CATINO, ANNA LUCIA FIORENZA
 Distribuzione geografica
Continente #
EU - Europa 164
NA - Nord America 157
AS - Asia 56
Totale 377
Nazione #
US - Stati Uniti d'America 150
IT - Italia 49
CN - Cina 23
FR - Francia 22
GB - Regno Unito 18
IN - India 15
IE - Irlanda 13
NL - Olanda 13
SG - Singapore 12
BA - Bosnia-Erzegovina 6
GR - Grecia 6
SE - Svezia 6
CA - Canada 4
DE - Germania 4
PL - Polonia 4
RS - Serbia 4
SI - Slovenia 4
ES - Italia 3
HR - Croazia 3
MX - Messico 3
AT - Austria 2
CH - Svizzera 2
DK - Danimarca 2
ID - Indonesia 2
ME - Montenegro 2
VN - Vietnam 2
IL - Israele 1
KR - Corea 1
RO - Romania 1
Totale 377
Città #
Chandler 30
Dublin 13
Milan 13
Amsterdam 12
Fairfield 10
Singapore 8
Ashburn 7
Cambridge 7
Rome 7
Banja Luka 6
London 6
Paris 6
Preveza 6
Wilmington 6
Woodbridge 6
Chaponost 5
Mumbai 5
Seattle 5
Turin 5
Belgrade 4
Brookline 4
Newcastle upon Tyne 4
Nyköping 4
Beijing 3
Chengdu 3
Chennai 3
Coyoacán 3
Genay 3
Houston 3
Hyderabad 3
Medford 3
Princeton 3
Torino 3
Toulouse 3
Vancouver 3
Zagreb 3
Andover 2
Atlanta 2
Bengaluru 2
Birmingham 2
Celje 2
Dong Ket 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Hangzhou 2
Jakarta 2
Lake Villa 2
Lenart v Slov. Goricah 2
Madrid 2
Messina 2
New Delhi 2
New York 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Sevenoaks 2
Shenzhen 2
Stockholm 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Ann Arbor 1
Brooklyn 1
Calgary 1
Cardito 1
Cluj-Napoca 1
Coventry 1
Frattamaggiore 1
Geneva 1
Guangzhou 1
Guiyang 1
Hebei 1
Hellikon 1
Jacksonville 1
Kettering 1
Krakow 1
Lancaster 1
Mannheim 1
Milanówek 1
Nanjing 1
Norwalk 1
Petah Tikva 1
Quanzhou 1
Redwood City 1
Rescaldina 1
Rotterdam 1
San Diego 1
Santa Clara 1
Seoul 1
Sesto San Giovanni 1
Shenyang 1
Troia 1
Valladolid 1
Warsaw 1
Totale 313
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 263
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 70
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 49
Totale 382
Categoria #
all - tutte 1.037
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.037


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202018 0 0 0 0 0 1 2 4 6 1 4 0
2020/202134 3 2 3 1 2 0 1 3 6 6 1 6
2021/202241 0 1 1 2 3 3 1 4 0 3 17 6
2022/2023163 9 15 5 9 12 23 17 17 26 14 10 6
2023/2024115 8 28 12 10 11 11 7 11 1 10 3 3
2024/202511 2 4 3 2 0 0 0 0 0 0 0 0
Totale 382